| Questions And Answer | Back Directory | [Structure]
PNC-27 contains a segment from human p53, residues 12–26, that is involved in the binding of p53 to HDM-2 connected to a membrane penetrating sequence called the membrane residency peptide (MRP). The sequence is H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH[3].
|
| Hazard Information | Back Directory | [Definition]
PNC-27 is an anticancer peptide, containing an HDM-2-binding domain. PNC-27 shows anti-tumor activity and can be used in acute myeloid leukemia research. | [in vitro]
PNC-27 (50 μg/mL; 0-3 h) induces cancer cell death.
PNC-27 (50 μg/mL; 15 min) binds to cell membrane-bound HDM-2. | [in vivo]
PNC-27 (intraperitoneal injection; 40 mg/kg; once daily; 2-3 w) shows anti-leukemia activity in vivo.
|
|
|